Atossa Therapeutics Inc (NASDAQ:ATOS) is down 20% in a month. The company announced its Q2 2021 financial results and offered corporate updates on recent development.
In Q2, the company received final findings from the open-label Phase II clinical study of oral Endoxifen during the “window of opportunity” between breast cancer diagnosis and surgery. Endoxifen achieved the primary endpoint in the study with a 65.1% reduction of Ki-67, which is a common tumor cell activity measure. Also, Swedish regulators gave the company authorization to commence Phase 2 clinical trial of Endoxifen in mammographic breast density reduction.
In addition, Australian regulators approved the commencement of the AT-H201 clinical study being developed for COVID-19 treatment. Atossa released final data from the Phase 1 randomized, double-blinded, sham-controlled study using its novel drug candidate AT-301, developed as a nasal spray for home use for patients diagnosed with COVID-19. The company is witnessing progress in its COVID-19 and MD programs. So, with the progress, ATOS is worth watching in the coming months.
On Monday, ATOS stock fell 2.80% to $3.13 with more than 4.30 million shares, compared to its average volume of 20.71 million shares. The stock has moved within a range of $3.0400 – 3.2100 after opening the trade at $3.18